Evommune is a biotechnology company that develops therapeutics that halt progressive disease and address their symptoms.
Evommune has raised $125.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in February 2026.
Evommune's investors include RA Capital Management, B Capital, FemHealth Ventures, Andera Partners, Longwood Fund.
Evommune is headquartered in Palo Alto, United States.
Evommune is a biotechnology company that develops therapeutics that halt progressive disease and address their symptoms.
Evommune is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Evommune — Funding & Investors." VCBacked, February 12, 2026, https://www.vcbacked.co/company/evommune. Accessed July 19, 2026.
VCBacked. (2026). Evommune — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/evommune
{{cite web |title=Evommune — Funding & Investors |url=https://www.vcbacked.co/company/evommune |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated